Viracta Q1 net loss $9.1M; positive NAVAL-1 trial ORR 50% in EBV+ PTCL

Viracta Therapeutics, Inc.

2024-Q1 EPS reported -$0.23

Net loss $9.1M ($0.23/shr) vs $12.2M in Q1 2023; cash $39.6M sufficient into late Q1 2025.
NAVAL-1 trial: Nana-val ORR 50%, complete response rate 20% in R/R EBV+ PTCL (n=10); median DoR maturing.
Plan to meet FDA mid-2024 for accelerated approval; Stage 1+2 data expected Q3 2024.
PMDA endorsed direct Japan enrollment into NAVAL-1 without prior Phase 1 safety study.
Phase 1b/2 solid tumor study: RP2D expected H2 2024; dose-optimization cohort by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viracta Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Viracta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-057130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.